abrdn plc Has $19.22 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

abrdn plc trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 15.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 82,102 shares of the medical research company’s stock after selling 15,302 shares during the period. abrdn plc’s holdings in IQVIA were worth $19,224,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its position in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth $27,000. Park Place Capital Corp bought a new position in shares of IQVIA during the 3rd quarter valued at $28,000. Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the 2nd quarter valued at $29,000. Finally, International Assets Investment Management LLC acquired a new position in shares of IQVIA during the 2nd quarter valued at about $32,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 4.7 %

Shares of NYSE:IQV opened at $205.82 on Friday. The company has a 50 day moving average of $235.10 and a 200-day moving average of $229.89. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The stock has a market cap of $37.52 billion, a price-to-earnings ratio of 26.73, a P/E/G ratio of 2.09 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

Analysts Set New Price Targets

A number of analysts have recently weighed in on IQV shares. Morgan Stanley boosted their price objective on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Truist Financial dropped their price target on IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research report on Monday, October 14th. Robert W. Baird raised their price objective on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research note on Friday, September 20th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, UBS Group increased their target price on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.27.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.